SYNCORE BIOTECHNOLOGY CO., LTD.
Booth No: M814
SynCoreBio is a public listed company (4192) established in 2008, focusing on new drugs research and development.
SynCoreBio owns a comprehensive pipeline with five new drugs:
SB01 (Phase2, Head and Neck Cancer)
SB02 (Pre-IND, Solid Tumors)
SB03 (FDA approved, External Genital Warts)
SB04 (Phase2, dry AMD)
SB05 (Phase3, Pancreatic Cancer/ Triple-Negative Breast Cancer)
Exhibitors you may be interested in